Dana Farber Cancer Institute has partnered with Fitbit to begin a 2-year randomized study that will investigate the affect of weight loss on breast cancer recurrence. The study, called the Breast Cancer Weight Loss (BWEL) study, is sponsored by the National Cancer Institute and the Alliance for Clinical Trials in Oncology.
“The increased threat of cancer recurrence linked to excess body weight threatens to limit our progress in treating breast cancer and preventing women from dying from this disease,” Jennifer Ligibel, a breast oncologist at Dana-Farber and lead investigator of the BWEL trial, stated in a statement. “If this study indicates that losing weight through increasing physical activity and decreasing calories makes better the survival rates in breast cancer, this could lead to weight loss and physical activity becoming a standard part of the treatment for millions of breast cancer patients around the world.”
No comments:
Post a Comment